# Beta Bionics Inc. (BBNX)

Source: https://www.quantisnow.com/company/BBNX
Generated: 2026-11-21T12:53:33.888Z

- Ticker: BBNX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- IPO year: 2025
- SEC CIK: 0001674632

## Latest BBNX news and filings

- 2026-11-18 21:23 UTC [SEC Form 4] [Chief Commercial Officer Mark Hopman exercised 775 shares at a strike of $5.10 and sold $12,570 worth of shares (775 units at $16.22) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-mark-hopman-exercised-775-shares-at-a-6798931)
- 2026-11-16 21:11 UTC [Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration](https://www.quantisnow.com/insight/senseonics-and-beta-bionics-launch-eversense-365-and-ilet-bionic-6794046)
- 2026-11-13 21:01 UTC [SEC Form 4] [Chief Financial Officer Feider Stephen exercised 8,874 shares at a strike of $5.10 and sold $152,681 worth of shares (8,874 units at $17.21) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-feider-stephen-exercised-8874-shares-at-a-6790355)
- 2026-11-12 21:45 UTC [SEC Form 4] [Chief Financial Officer Feider Stephen exercised 744 shares at a strike of $5.10 and sold $12,649 worth of shares (744 units at $17.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-feider-stephen-exercised-744-shares-at-a-6788586)
- 2026-11-09 21:30 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-beta-bionics-inc-6781673)
- 2026-11-09 21:26 UTC [SEC Form 4] [Chief Financial Officer Feider Stephen exercised 382 shares at a strike of $5.10 and sold $6,508 worth of shares (382 units at $17.04) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-feider-stephen-exercised-382-shares-at-a-6781629)
- 2026-11-04 21:08 UTC [SEC Form 4] [Chief Commercial Officer Hopman Mark sold $6,253 worth of shares (370 units at $16.90) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 54,143 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-hopman-mark-sold-6253-worth-of-shares-6772552)
- 2026-11-03 12:30 UTC [Beta Bionics Announces Participation at Upcoming Investor Conferences](https://www.quantisnow.com/insight/beta-bionics-announces-participation-at-upcoming-investor-conferences-6768424)
- 2026-10-30 14:15 UTC [Market Insight] [BBNX UPCOMING DEADLINE: Levi & Korsinsky Alerts Beta Bionics, Inc. Stockholders of Securities Class Action - Contact the Firm](https://www.quantisnow.com/insight/bbnx-upcoming-deadline-levi-korsinsky-alerts-beta-bionics-inc-stockholders-6764818)
- 2026-10-29 20:22 UTC [SEC Form 4] [Chief Product Officer Mensinger Mike sold $58,300 worth of shares (2,650 units at $22.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-product-officer-mensinger-mike-sold-58300-worth-of-shares-6763788)
- 2026-10-28 20:03 UTC [SEC Form 4] [Chief Commercial Officer Hopman Mark sold $16,420 worth of shares (821 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-hopman-mark-sold-16420-worth-of-shares-6761237)
- 2026-10-27 20:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Beta Bionics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-beta-bionics-inc-6759410)
- 2026-10-27 20:04 UTC [SEC Form 8-K] [SEC Form 8-K filed by Beta Bionics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-beta-bionics-inc-6759200)
- 2026-10-27 20:02 UTC [Public Offering] [Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance](https://www.quantisnow.com/insight/beta-bionics-announces-third-quarter-2026-financial-results-and-updates-6759097)
- 2026-10-19 23:20 UTC [INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law Firm](https://www.quantisnow.com/insight/investor-action-notice-moore-law-pllc-encourages-investors-in-beta-6751111)
- 2026-10-16 20:10 UTC [SEC Form 4] [Chief Commercial Officer Hopman Mark sold $13,446 worth of shares (775 units at $17.35) (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-hopman-mark-sold-13446-worth-of-shares-6749183)
- 2026-10-16 14:40 UTC [Market Insight] [BBNX DEADLINE: Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of Upcoming Securities Class Action Deadline](https://www.quantisnow.com/insight/bbnx-deadline-levi-korsinsky-reminds-beta-bionics-inc-investors-of-6748927)
- 2026-10-12 12:47 UTC [Analyst Coverage Initiated] [Jefferies initiated coverage on Beta Bionics with a new price target](https://www.quantisnow.com/insight/jefferies-initiated-coverage-on-beta-bionics-with-a-new-price-6743582)
- 2026-10-09 14:50 UTC [Market Insight] [BBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky](https://www.quantisnow.com/insight/bbnx-investor-alert-beta-bionics-inc-securities-class-action-notice-6742618)
- 2026-10-07 18:56 UTC [SEC Form SCHEDULE 13G filed by Beta Bionics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-beta-bionics-inc-6740182)
- 2026-10-07 12:46 UTC [Analyst Coverage Initiated] [Barclays initiated coverage on Beta Bionics with a new price target](https://www.quantisnow.com/insight/barclays-initiated-coverage-on-beta-bionics-with-a-new-price-6739897)
- 2026-10-05 21:11 UTC [SEC Form 4] [Chief Commercial Officer Hopman Mark sold $7,015 worth of shares (370 units at $18.96) (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-hopman-mark-sold-7015-worth-of-shares-6737471)
- 2026-09-29 12:00 UTC [Earnings Date] [Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026](https://www.quantisnow.com/insight/beta-bionics-to-announce-third-quarter-2026-financial-results-on-6728409)
- 2026-09-23 21:40 UTC [SEC Form 4] [Director Jones Christy sold $147,890 worth of shares (6,430 units at $23.00) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 19,564 units (SEC Form 4)](https://www.quantisnow.com/insight/director-jones-christy-sold-147890-worth-of-shares-6430-units-6724505)
- 2026-09-23 12:36 UTC [Analyst Coverage Initiated] [Wells Fargo initiated coverage on Beta Bionics with a new price target](https://www.quantisnow.com/insight/wells-fargo-initiated-coverage-on-beta-bionics-with-a-new-6723778)
- 2026-09-22 11:30 UTC [Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365](https://www.quantisnow.com/insight/beta-bionics-announces-agreement-integrate-the-ilet-bionic-pancreas-and-6722338)
- 2026-09-18 23:51 UTC [SEC Form 4] [Amendment: Chief Commercial Officer Hopman Mark sold $664,550 worth of shares (35,994 units at $18.46) as part of a pre-agreed trading plan, decreasing direct ownership by 29% to 88,033 units (SEC Form 4)](https://www.quantisnow.com/insight/amendment-chief-commercial-officer-hopman-mark-sold-664550-worth-of-6720993)
- 2026-09-17 20:15 UTC [SEC Form 4] [Chief Commercial Officer Hopman Mark sold $619,640 worth of shares (30,779 units at $20.13) as part of a pre-agreed trading plan, decreasing direct ownership by 35% to 56,479 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-hopman-mark-sold-619640-worth-of-shares-6719203)
- 2026-09-17 20:15 UTC [SEC Form 4] [Chief Product Officer Mensinger Mike sold $58,300 worth of shares (2,650 units at $22.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 177,390 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-product-officer-mensinger-mike-sold-58300-worth-of-shares-6719202)
- 2026-09-17 20:05 UTC [Public Offering] [Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock](https://www.quantisnow.com/insight/beta-bionics-announces-closing-of-1725-million-public-offering-of-6719010)
- 2026-09-16 00:13 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Beta Bionics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-beta-bionics-inc-6716774)
- 2026-09-16 00:15 UTC [SEC Form FWP] [SEC Form FWP filed by Beta Bionics Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-beta-bionics-inc-6716764)
- 2026-09-16 03:56 UTC [Public Offering] [Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants](https://www.quantisnow.com/insight/beta-bionics-announces-pricing-of-public-offering-of-common-stock-6716740)
- 2026-09-15 20:58 UTC [SEC Form 8-K] [Beta Bionics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/beta-bionics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6716405)
- 2026-09-15 20:15 UTC [SEC Form 4] [Chief Commercial Officer Hopman Mark sold $12,028 worth of shares (775 units at $15.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.89% to 86,382 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-hopman-mark-sold-12028-worth-of-shares-6716162)
- 2026-09-15 20:13 UTC [Public Offering] [Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock](https://www.quantisnow.com/insight/beta-bionics-announces-proposed-public-offering-of-1250-million-of-6716109)
- 2026-09-14 11:30 UTC [Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm](https://www.quantisnow.com/insight/beta-bionics-announces-fda-clearance-of-mint-the-companys-transformative-6713704)
- 2026-09-14 11:00 UTC [Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas](https://www.quantisnow.com/insight/senseonics-announces-strategic-partnership-with-beta-bionics-to-integrate-eversense-6713637)
- 2026-09-10 20:30 UTC [SEC Form 4] [Chief Commercial Officer Hopman Mark sold $680,723 worth of shares (36,870 units at $18.46) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 87,157 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-hopman-mark-sold-680723-worth-of-shares-6711807)
- 2026-09-04 21:19 UTC [SEC Form 4] [President & CEO Saint Sean sold $113,259 worth of shares (5,641 units at $20.08) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 398,429 units (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-saint-sean-sold-113259-worth-of-shares-5641-6706943)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BBNX
- Earnings history: https://www.quantisnow.com/earnings/BBNX
- Dividend history: https://www.quantisnow.com/dividends/BBNX
- Insider transactions: https://www.quantisnow.com/insiders/BBNX
- Options chain: https://www.quantisnow.com/options/BBNX
- SEC 8-K filings only: https://www.quantisnow.com/company/BBNX/8-k
- RSS and alerts for BBNX: https://www.quantisnow.com/docs/rss-feeds.md
